Clinical applications of circulating tumor cells detection in gastric carcinoma

doi:10.3760/cma.j.issn.1673-422X.2015.06.018

Abstract

Abstract: Circulating tumor cells (CTCs) are special kind of tumor cells in the peripheral blood of patient with tumor. Now CTCs detection has been used in the survival time prediction, postoperational recurrence detection, individualized treatment and other aspects in the patients with gastric cancer. As the research going, CTCs will provide new help for the comprehensive treatment of gastric cancer.

Key words: Stomach neoplasms, Therapy, Circulating tumor cells, Detection

Lu Xinyang, Cui Kai, Li Sheng. Clinical applications of circulating tumor cells detection in gastric carcinoma[J]. Journal of International Oncology, 2015, 42(6): 466-468.

References

［1］ Uenosono Y, Arigami T, Kozono T, et al. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer［J］. Cancer, 2013, 119(22): 3984-3991. ［2］ Steinert G, Schlch S, Koch M, et al. Biology and significance of circulating and disseminated tumour cells in colorectal cancer［J］. Langenbecks Arch Surg, 2012, 397(4): 535-542. ［3］ Hong B, Zu Y. Detecting circulating tumor cells: current challenges and new trends［J］. Theranostics, 2013, 3(6): 377-394. ［4］ Vaiopoulos AG, Kostakis ID, Gkioka E, et al. Detection of circulating tumor cells in colorectal and gastric cancer using a multiplex PCR assay［J］. Anticancer Res, 2014, 34(6): 3083-3092. ［5］ Dardaei L, Shahsavani R, Ghavamzadeh A, et al. The detection of disseminated tumor cells in bone marrow and peripheral blood of gastric cancer patients by multimarker (CEA, CK20, TFF1 and MUC2) quantitative realtime PCR［J］. Clin Biochem, 2011, 44(4): 325-330. ［6］ Arigami T, Uenosono Y, Hirata M, et al. B7H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells［J］. Cancer Sci, 2011, 102(5): 1019-1024. ［7］ Tsujiura M, Ichikawa D, Konishi H, et al. Liquid biopsy of gastric cancer patients: circulating tumor cells and cellfree nucleic acids［J］. World J Gastroenterol, 2014, 20(12): 3265-3286. ［8］ Zheng Y, Cui L, Sun W, et al. MicroRNA21 is a new marker of circulating tumor cells in gastric cancer patients［J］. Cancer Biomark, 2011—2012, 10(2): 71-77. ［9］ Raimondi C, Gradilone A, Naso G, et al. Clinical utility of circulating tumor cell counting through CellSearch(?): the dilemma of a concept suspended in Limbo［J］. Onco Targets Ther, 2014, 7: 619-625. ［10］ Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with smallcell lung cancer［J］. J Clin Oncol, 2012, 30(5): 525-532. ［11］ Sirop S, Kanaan M, Korant A, et al. Detection and prognostic impact of micrometastasis in colorectal cancer［J］. J Surg Oncol, 2011, 103(6): 534-537. ［12］ Hwang SG, Kim KM, Cheong JH, et al. Impact of pretreatment thrombocytosis on bloodborne metastasis and prognosis of gastric cancer［J］. Eur J Surg Oncol, 2012, 38(7): 562-567. ［13］ Zhang ZY, Ge HY. Micrometastasis in gastric cancer［J］. Cancer Lett, 2013, 336(1): 34-45. ［14］ Yoneda A, Taniguchi K, Torashima Y, et al. The detection of gastric cancer cells in intraoperative peritoneal lavage using the reverse transcriptionloopmediated isothermal amplification method［J］. J Surg Res, 2014, 187(1): e1-6. ［15］ Cao W, Yang W, Li H, et al. Using detection of survivinexpressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer［J］. J Surg Oncol, 2011, 103(2): 110-115. ［16］ Arigami T, Uenosono Y, Ishigami S, et al. Clinical significance of stanniocalcin 2 expression as a predictor of tumor progression in gastric cancer［J］. Oncol Rep, 2013, 30(6): 2838-2844. ［17］ Farace F, Massard C, Vimond N, et al. A direct comparison of CellSearch and ISET for circulating tumourcell detection in patients with metastatic carcinomas［J］. Br J Cancer, 2011, 105(6): 847-853. ［18］ Hiraiwa K, Takeuchi H, Hasegawa H, et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers［J］. Ann Surg Oncol, 2008, 15(11): 3092-3100. ［19］ Matsusaka S, Chìn K, Ogura M, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer［J］. Cancer Sci, 2010, 101(4) :1067-1071. ［20］ Khushalani NI. Phase Ⅰ and Ⅱ clinical trials for gastric cancer［J］. Surg Oncol Clin N Am, 2012, 21(1): 113-128. ［21］ Galletti G, Sung MS, Vahdat LT, et al. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2based microfluidic device［J］. Lab Chip, 2014, 14(1): 147-156. ［22］ Ross JS. Update on HER2 testing for breast and upper gastrointestinal tract cancers［J］. Biomark Med, 2011, 5(3): 307-318.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[5]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[6]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[7]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[8]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[9]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[10]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[11]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[12]	Hu Tingting, Wang Yuehua. Electronic nose and nematode nose as new tool for early cancer screening [J]. Journal of International Oncology, 2024, 51(4): 223-226.
[13]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[14]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[15]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.